Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1292
  • Dowloads 146

Original Research

Open Access

Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer

  • H. Nomura1
  • H. Tsuda1,*,
  • F. Kataoka1
  • T. Chiyoda1
  • W. Yamagami1
  • E. Tominaga1
  • N. Susumu1
  • D. Aoki1

1Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan

DOI: 10.12892/ejgo20120186 Vol.33,Issue 1,January 2012 pp.86-89

Published: 10 January 2012

*Corresponding Author(s): H. Tsuda E-mail: htsud@sc.itc.keio.ac.jp

PDF (105.86 kB) View Full-text

Abstract

Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m(2)) was administered intravenously on days I, 8 and 15 every four weeks. PLD (50 mg/m2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05). respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-II group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

Keywords

Ovarian cancer; Recurrence; Platinum-resistant; Irinotecan; Liposomal doxorubicin

Cite and Share

H. Nomura,H. Tsuda,F. Kataoka,T. Chiyoda,W. Yamagami,E. Tominaga,N. Susumu,D. Aoki. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2012. 33(1);86-89.

URL:

https://www.ejgo.net/articles/10.12892/ejgo20120186

References

[1] Japan Society of Gynecologic Oncology. Ovarian Cancer Treatment Guidelines 2007. Tokyo, Japan, Kanehara & Co., Ltd; 2007.

[2] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[3] The National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 2. 2010). Database online, 2010.

[4] Matsumoto K., Katsumata N., Yamanaka Y., Yonemori K., Kohno T., Shimizu C et al.: “The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer”. Gynecol. Oncol., 2006, 100, 412.

[5] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A. et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[6] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: “Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan”. J Clin Oncol. 2001, 19, 3312.

[7] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D. et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[8] ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I. et al.: “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer”. J. Clin. Oncol., 1997, 15, 2183.

Submission Turnaround Time

Top